Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2

Abstract Background Despite effective LDL-C lowering treatments, patients with mixed hyperlipidemia remain at high ASCVD residual risk attributed to cholesterol transported by LDL and triglyceride (TG)-rich lipoproteins (TRLs). Angiopoietin-like protein 3 (ANGPTL3) regulates lipoprotein metabolism in both the exogenous and endogenous pathways by inhibiting lipoprotein lipase, endothelial lipase and cellular lipoprotein uptake. Naturally-occuring ANGPTL3 loss-of-function variant carriers have lower levels of LDL-C, non-HDL-C, and TGs and reduced ASCVD risk. Zodasiran, an investigational RNAi therapeutic, inhibits hepatic ANGPTL3 expression. Aim To report the long-term efficacy and safety of zodasiran in adults with mixed hyperlipidemia (fasting TG 2-5.64 mmol/L and LDL-C ≥1.8-mmol/L or non-HDL-C ≥2.59-mmol/L. Methods 156 patients entering the OLE, of 204 originally randomized 3:1 to zodasiran 50/100/200mg or placebo subcutaneously on Day1 and Week12, received zodasiran 200mg quarterly during the extension period. Results Zodasiran reduced ANGPTL3, TG, non-HDL-C, apoB, and Remnant-cholesterol from baseline in a dose-dependent manner compared with placebo. By Month1 of the OLE, % change from baseline of TG attained levels were comparable to those in the main study, including among subjects previously on placebo. Durable and sustained reductions in mean % (SD) levels from baseline were -57.9% (22.9) for ANGPTL3; -55.9% (16.3) for TG, -30.1% (21.6) for non-HDL-C, -61.8% (21.2) for Remnant-cholesterol, -9.9% (30.6) for LDL-C, -15.8% (20.8) for apoB, -28.5% (17.9) for total cholesterol, and -19.9% (22.4) for HDL-C occurred in the extension from 1-month post-dose through 24 months. TEAEs occurred in 77.8%; serious AEs were reported in 13.5% of patients; 3.2% discontinued due to an AE. The most common AEs were COVID-19, upper respiratory tract infection, urinary tract infection, headache, Type 2 Diabetes Mellitus, sinusitis, and arthralgia. Conclusions Zodasiran delivered substantial and sustained reductions in ANGPTL3, TG, and atherogenic lipoproteins in patients with mixed hyperlipidemia, with a favorable safety profile, consistent with observations from the blinded portion of the study. The cardiovascular effects remain to be determined.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.